Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action

Intern Emerg Med. 2020 Nov;15(8):1573-1576. doi: 10.1007/s11739-020-02504-y. Epub 2020 Oct 3.

Authors

Rosario Rossi¹, Marisa Talarico², Francesca Coppi², Giuseppe Boriani²

Affiliations

¹ Cardiology Unit, Policlinico Di Modena Hospital, University of Modena and Reggio Emilia, Via del Pozzo 71, 41124, Modena, Italy. rosario.rossi@unimore.it.
² Cardiology Unit, Policlinico Di Modena Hospital, University of Modena and Reggio Emilia, Via del Pozzo 71, 41124, Modena, Italy.

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Analysis of Variance
COVID-19
Coronavirus Infections / drug therapy*
Coronavirus Infections / physiopathology
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacokinetics*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Male
Middle Aged
Pandemics / statistics & numerical data
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / physiopathology

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors